Sona Successfully Completes FDA-Required Toxicity Study

Stock Information for Sona Nanotech Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sona Nanotech Inc - Ordinary Shares

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
BioVaxys and Sona Nanotech Enter Research Collaboration
Sona Nanotech Announces Annual Options Grants
Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model
Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11
Sona Nanotech's Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.